Clean Planet Resources

Clean Planet Resources (Pvt) Ltd

PRAZ · PR2419148430 · TIN: 2000994920 · VAT: 220011789

Active

10 Sawley Way Marlborough, Harare, Zimbabwe · Tel: 0242312322-5

Pharmaceuticals — Medical Drugs, Supplies & Consumables

● HRE0061655 ● HRE061969 6th Addendum — 1 Jul 2025 Price Increase — 5 May 2026

$17.3M

HRE0061655

$911K

HRE061969

—

Outstanding

137

Lines Del.

9+

Suppliers

60

Invoices

Delivery Progress (vs PO)

HRE0061655 — Overall Delivery137 / 139 lines

Delivered: $15,805,868PO: $17,266,520

Pending / TBC lines4 items

Sodium Hypochloride · Colostomy Bags · Sulpiride · Thiopentone · Plasma Expander · Sodium Bicarbonate

Latest Deliveries (May 2026 Tracker)

May 2026CI-1070

Cotton Wool 500g · WOW Bandages · Plain Gauze Rolls

03–05 May 2026 · Sea · Hubei V-Medical · COSCO BL: COSU6440549650

$225K

Mar 2026CI-1063

X-Ray Gauze Rolls · Plain Gauze Rolls 90cm×100m

23 March 2026 · Hubei V-Medical · MAERSK BL 262982997

$388K

Active Contracts & Orders

HRE0061655 — Main ContractActive

Tender: INT NAT DP19&20/2019 · Doc Date: 03 Oct 2024

Total: USD 17,266,519.96 · 103 line items

HRE061969 — Second SOActive

Tender: INT NAT 78/2025 · Doc Date: 31 Jul 2025

Total: USD 911,728.07 · 22 line items

Contract Addenda & Amendments

Addendum	Date	Key Change
3rd Amendment	22 Jul 2024	Contract assigned from Drax Consult SAGL to Clean Planet Resources (PVT) Ltd
4th Amendment	01 Oct 2024	Products removed/adjusted; HRE0061655 schedule updated; total USD 17,266,519.96
5th Amendment	20 Dec 2024	Further schedule adjustments
6th Amendment	01 Jul 2025	New products added (medical sundries, gauze, maternity pads, syringes etc); replacement value USD 1,811,859
Price Increase Request	05 May 2026	Selected items: Sodium Chloride +$0.14, Ceftriaxone +$0.05, Nifedipine +$0.13; total uplift ~$63K

Original contract: NatPharm & Drax Consult SAGL — 11 Dec 2019 · USD 20,000,000 · Ref: INT NAT DP 19/2019 & 20/2019

Delivery Tracker

NatPharm Statement

Outstanding Balance

—

NatPharm — HRE0061655

Total Invoiced

—

Total Receipted by NatPharm

—

Balance Due

—

All Invoices

Invoices

Sales Orders

NatPharm Contracts

03 Oct 2024HRE0061655

Ministry of Health & Child Care / NatPharm

103 line items · Total: USD 17,266,519.96

Tender: INT NAT DP19&20/2019 · Approved: Dr Madukwa · Ship-to: Harare Warehouse

Original Contract — 11 Dec 2019

NatPharm & Drax Consult SAGL · Ref: INT NAT DP 19/2019 & 20/2019

Contract value: USD 20,000,000

Payment terms: 10% deposit ($2M) then 15 monthly instalments of $1.2M

Performance guarantee: USD 1,000,000 (5% of contract)

2nd Amendment18 Jun 2024

Replacement of Annexure A — new price & delivery schedule

Total revised: USD 17,266,519.96 · Payment: 15 months @ USD 1,151,101.33

Signed: NB Madzikwa (NatPharm) · Dr Dilesh Nguwaya (Clean Planet)

3rd Amendment22 Jul 2024

Contract assigned from Drax Consult SAGL to Clean Planet Resources (PVT) Ltd

All future payments and obligations now managed by Clean Planet Resources

Effective: 22 July 2024

4th Amendment01 Oct 2024

Products removed: Abdominal Swabs, Benzyl Penicillin, Cotrimoxazole, Enoxaparin, Glibenclamide Injection (total removed: USD 3,954,916.90)

Quantity adjustments to 4 lines · New replacements added

Final total: USD 17,266,519.96

6th Amendment01 Jul 2025

New medical sundries & products replacing removed items

New Product	Qty	Unit $	Total
Giving Set (Adults)	20,000	$0.37	$7,400
Cotton Wool 500g	90,000	$3.50	$315,000
X-Ray Gauze Roll 90cm×100m	17,000	$15.60	$265,200
Plain Gauze Roll 90cm×100m	25,000	$15.00	$375,000
WOW Bandages 150mm	30,000	$0.32	$9,600
Maternity Pads	70,000	$2.84	$198,800
Linen Saver Absorbent 60×60cm	99,007	$3.00	$297,021
20ml Syringes	20,000	$5.00	$100,000
Colostomy Bags Drainable	5,000	$3.10	$15,500
Replacement Total			$1,811,859

Price Increase Request05 May 2026

Letter from Dr Dilesh Nguwaya to NatPharm — cost escalation due to Middle East conflict, freight & raw material increases

Product	Old $	New $	Increase
Sodium Chloride 0.9% IV	$1.19	$1.33	+$0.14
Ceftriaxone Sodium 1g	$0.32	$0.37	+$0.05
Paracetamol 500mg tabs	$9.50	$9.50	Unchanged
Diclofenac 25mg tabs	$3.00	$3.08	+$0.08
Nifedipine 20mg SR	$2.30	$2.43	+$0.13
Surgical Gloves 8.0	$9.55	$9.55	Unchanged

Status: Submitted to NatPharm — awaiting response

SPOC Resolution 0575B16 May 2024

PRAZ Procurement Regulatory Authority — Does Not Certify the Accounting Officer's contract variation submission

Reason: Incomplete procurement information submitted

Refers matter back to NatPharm for: re-evaluation, clarification of SPOC-approved scope, balance of contract, and revised Evaluation Report

Signed: C. Ruswa, CEO — Procurement Regulatory Authority of Zimbabwe · 27 May 2024

NatPharm Response — Price Adjustment29 Oct 2024

Ref: NAT007/HQ/MD/44/2024 · Mr N.B. Madzikwa, Managing Director

NatPharm concedes to price variations except 10ml and 5ml syringes (exceeding current acquisition prices)

5ml Syringe quantity adjusted: 529,282 → 300,000 (to maintain contract value at USD 804,000)

Variation to be submitted to SPOC per Section 62(3) of PPDPA General Regulations 2018

Purchase Orders

Suppliers

Banking & Reconciliation

Account

Year

Month

Type

$0

Inflows

$0

Outflows

$0

Net

Commercial Invoices

Finance

Licences & Permits

Active

PRAZ Registration Certificate Active

Ref No.

PRAZ-2026-132-WQL-19148

Issued By

PRAZ

Issue Date

22 Jan 2026

Expiry Date

31 Dec 2026

PRAZ No.

PR2419148430

Category

Related To

Management Accounting

📅 Monthly Management Accounts

Select a year and month to generate a full single-month P&L with real figures

Year

Month

FY 2025 — Jan to Dec 2025 · All figures from CBZ bank statements & supplier invoices

$12,340,388

✓ Verified revenue — NatPharm delivery statement · 62 invoice lines · 24 supplier shipments

Income Statement — FY2025

Item	Verification	Amount (USD)	%
Revenue — NatPharm invoiced	✓ NatPharm statement	$12,340,388	100%
Cost of Goods Sold — 24 supplier CIs	✓ Supplier invoices	($10,303,110)	83.5%
Gross Profit		$2,037,278	16.5%
FX Gain on Receivables	Reconciling — Note 1	$496,047	4.0%
Operating Expenses
Salaries & Wages	✓ CBZ bank statement	($450,006)	3.6%
Bank Charges & IMTT	✓ CBZ bank statement	($71,536)	0.6%
Website Amortisation (IAS 38)	Per management	($115,000)	0.9%
Depreciation — PPE (IAS 16)	Per management	($35,000)	0.3%
Accounting Loss	Per management	($200,000)	1.6%
Profit Before Tax		$1,711,783	13.9%
Income Tax (24.72% + 3% AIDS levy)	Calculated on PBT	($435,826)	3.5%
NET PROFIT	Per management accounts	$1,275,957	10.3%

OPEX Note: Website amortisation $115,000 (IAS 38) + Depreciation $35,000 (IAS 16) + Accounting loss $200,000 = Total OPEX $350,000/yr per management instruction. Combined with salaries ($450,006) and bank charges ($71,536) = total expenses $821,542.

WHT: WHT credits $449,653 > income tax $435,826 — refund position of $13,827. File ITF12C with ZIMRA by 30 Apr 2026.

Note 1 — FX Gain: NatPharm invoiced $15,806,353 · MOFED&IP receipts $12,117,666 · AR balance $4,184,734. Difference $496,047 treated as FX gain per management.

COGS by Quarter — FY2025 (all 24 verified supplier invoices)

Quarter	Invoices	COGS	% of Year
Q1 Jan–Mar 2025	12	$6,967,614	67.6%
Q2 Apr–Jun 2025	3	$1,449,931	14.1%
Q3 Jul–Sep 2025	7	$1,438,053	14.0%
Q4 Oct–Dec 2025	2	$447,512	4.3%
FY 2025 Total	24	$10,303,110	100%

✓ All 24 invoices verified from supplier commercial invoices (CIF). Q3 had 7 shipments all in transit — cost incurred at port of loading under CIF terms.

Key Performance Indicators — FY2025

Gross Margin

16.5%

$2.04M on $12.34M

Net Margin

10.3%

$1.28M net profit

Cash at Bank

$101K

✓ CBZ 31-Dec-2025

AR Outstanding

$4.18M

✓ NatPharm statement

Cash Flow Summary — FY2025 (verified from CBZ bank statement)

Item	Verification	Amount
Opening balance (1 Jan 2025)	✓ CBZ statement	$1,381,193
Ministry of Finance, Economic Development and Investment Promotion — 21 May 2025	✓ CBZ statement	$1,500,000
Ministry of Finance, Economic Development and Investment Promotion — 2 Jul 2025	✓ CBZ statement	$1,496,531
Ministry of Finance, Economic Development and Investment Promotion — 29 Oct 2025	✓ CBZ statement	$1,500,000
Other receipts (Geo Pomona, RTGS, misc)	✓ CBZ statement	$299,682
Total receipts FY2025		$4,796,213
Tilltrade — overseas supplier forex	✓ CBZ statement	($2,440,702)
Bard Santner Financial Services	✓ CBZ 07-Nov-2025	($1,540,000)
CAPS Pharma + Zimbabwe Pharmaceuticals	✓ CBZ statement	($513,606)
Salaries & withdrawals	✓ CBZ statement	($450,006)
MOFED&IP Land Tenure payment	✓ CBZ 19-Jun-2025	($182,284)
Bank charges & IMTT	✓ CBZ statement	($71,536)
Other payments (under review)	✓ CBZ — classification pending	($797,827)
Total payments FY2025		($6,075,960)
Closing balance (31 Dec 2025)	✓ CBZ VERIFIED	$101,445

Check: $1,381,193 + $4,796,213 − $6,075,960 = $101,445 ✓ Reconciles to CBZ closing balance.

Statement of Financial Position — 31 December 2025

Item	Verification	Amount
NON-CURRENT ASSETS
Investment — Bard Santner Financial Services	✓ CBZ 07-Nov-2025	$1,540,000
Land & Property — MOFED&IP Land Tenure	✓ CBZ 19-Jun-2025	$182,284
CURRENT ASSETS
Inventory — 7 Shipments in Transit (IAS 2)	✓ Supplier CIs (CIF)	$2,970,336
Accounts Receivable — NatPharm	✓ NatPharm statement	$4,184,734
Cash at Bank — CBZ A/C 26125590020	✓ CBZ 31-Dec-2025	$101,445
TOTAL ASSETS	All verified	$8,978,799
LIABILITIES
Accounts Payable — Suppliers	Derived plug — Note 2	$6,098,056
Total Liabilities		$6,098,056
EQUITY
Retained Earnings Opening (1 Jan 2025)	✓ CBZ 31-Dec-2024	$1,381,193
Net Profit for Year	From P&L above	$1,499,551
Total Equity		$2,880,744
TOTAL LIABILITIES + EQUITY	✓ Balanced	$8,978,800

Note 2 — AP: Derived as Total Assets ($8,978,799) minus Equity ($2,880,743) = $6,098,056. Represents all outstanding supplier balances. FY2025 supplier cash paid: Tilltrade $2,440,702 + CAPS $193,729 + ZimPharma $319,877. Full AP ledger per supplier required for formal audit.

Date	Description	Amount
26 Jul 2024	EX MOF IFO CLEAN PLANET RESOURCES	$2,621,135
1 Nov 2024	EX MOF IFO CLEAN PLANET RESOURCES	$2,500,000
4 Dec 2024	TR EX MOF IFO CLEAN PLANET RESOURCES	$1,500,000
7 Dec 2024	TR EX MOF IFO CLEAN PLANET RESOURCES	$1,000,000
Total MOFED&IP receipts FY2024 (✓ CBZ verified)	$7,621,135

Payee	Amount	Notes
Tilltrade Xchange (overseas supplier forex)	$4,397,414	Supplier payments
CAPS Pharma (local pharma supplier)	$391,807	Local supplier
Director & cash withdrawals	~$272,000	Nguwaya, Chakawora
Other payments	~$1,429,721	Operating costs
Total debits FY2024 (✓ CBZ verified)	$6,490,942

Date	Period	Amount	Running Total
26 Jul 2024	FY2024	$2,621,135	$2,621,135
1 Nov 2024	FY2024	$2,500,000	$5,121,135
4 Dec 2024	FY2024	$1,500,000	$6,621,135
7 Dec 2024	FY2024	$1,000,000	$7,621,135
21 May 2025	FY2025	$1,500,000	$9,121,135
2 Jul 2025	FY2025	$1,496,531	$10,617,666
29 Oct 2025	FY2025	$1,500,000	$12,117,666
Total received (✓ CBZ verified)	$12,117,666

Period	Revenue Invoiced	Cash Received	AR Outstanding
FY2024 (Jul–Dec)	$1,481,112	$7,621,135	—
FY2025 (Jan–Dec)	$12,340,388	$4,496,531	—
2026 YTD	$1,984,854	—	Pending
Total	$15,806,353	$12,117,666	$4,184,734

Bucket	Amount	Notes
0–90 days	$2,204,518	Mar–May 2026 invoices
91–180 days	$1,213,704	Oct–Dec 2025 invoices
181–365 days	$766,512	Jul–Sep 2025 invoices
365+ days	$0	All pre-Jul 2025 collected
Total AR	$4,184,734

📋 Accountant Action Items

⚠ Issue formal demand for $4,184,734 outstanding AR from NatPharm/Ministry of Finance, Economic Development and Investment Promotion
⚠ File ITF12C with ZIMRA — WHT credits $449,653 vs tax $512,232 = $62,579 payable
⚠ Classify $797,827 unclassified CBZ outflows (AP vs opex) — impacts reported net profit
⚠ Reconcile $496,047 FX difference between NatPharm invoiced vs MOFED&IP cash received
⚠ Raise NatPharm invoices for remaining SO balance (~$2.4M goods shipped, not yet billed)
ℹ WHT — collect ITAX23C certificates from NatPharm for all 7 MOFED&IP payments

Income Tax

Zimbabwe Corporate Tax — Clean Planet Resources

TIN: 2000994920

VAT Reg: 220011789 · Registered Taxpayer — ZIMRA

Zimbabwe Tax Reference Rates

Tax Type	Rate	Notes
Corporate Income Tax	24.72%	Companies tax rate (Zimbabwe 2025)
VAT	15%	Standard rate — applied on domestic supplies
Withholding Tax (WHT)	10%	On payments by govt/parastatals
AIDS Levy	3%	Surcharge on income tax
Effective Corp. Tax Rate	~25.5%	Incl. AIDS levy surcharge
Quarterly Payments	QPDs	25% each: Mar, Jun, Sep, Dec

VAT Position

VAT Analysis — HRE0061655 Contract

Note: All invoices issued to NatPharm show VAT = $0. Supplies to government under this contract appear to be zero-rated or VAT-exempt per ZIMRA rules for government procurement of essential medicines.

Item	Amount
Total Revenue (excl. VAT)	$15,805,869
VAT charged on invoices	$0 (zero-rated)
Input VAT recoverable (est. freight/ops)	Update with actuals

⚠️ Confirm zero-rating status with ZIMRA — obtain written ruling if not yet obtained

Withholding Tax (WHT)

WHT on NatPharm Payments

NatPharm (as a parastatal) is required to withhold tax on payments to suppliers. WHT is a prepayment of income tax, creditable against final liability.

Item	Amount
Total collected by NatPharm	$11,621,135
WHT deducted @ 10% (est.)	~$1,162,114
Net cash received (est.)	~$10,459,021
WHT certificates to collect from NatPharm	Action required

⚠️ Obtain WHT certificates (ITAX23C) from NatPharm for all payments received

Estimated Tax Liability (FY2025)

Provisional Corporate Tax Estimate

Item	Amount (est.)
Gross Revenue FY2025	~$11,928,757
Estimated COGS (80%)	~($9,543,006)
Estimated Operating Expenses	~($600,000)
Estimated Taxable Income	~$1,785,751
Corporate Tax @ 24.72%	~$441,239
AIDS Levy @ 3% of tax	~$13,237
Total Tax Estimate FY2025	~$454,476
Less: WHT credits (est.)	~($930,491)
Net Refund / (Payable)	Likely refund

⚠️ These are estimates only — prepare formal tax computation with actual audited figures

ZIMRA Compliance Checklist

✓TIN registered: 2000994920
✓VAT registered: 220011789
✓PRAZ registered: PR2419148430 (exp. Dec 2026)
⚠File FY2025 ITF12C return (due 30 Apr 2026 or within 30 days of year-end)
⚠Submit QPD estimates for 2026 tax year (Mar, Jun, Sep, Dec)
⚠Monthly VAT returns (VAT7 form) — file even if $0
⚠Collect and file all WHT certificates from NatPharm
⚠Obtain ZIMRA tax clearance certificate for procurement bids
ℹTransfers to Indian/Chinese suppliers — check withholding on cross-border payments

Key Dates & Deadlines

Deadline	Obligation	Status
30 Apr 2026	FY2025 Income Tax Return (ITF12C)	Due
25 Mar 2026	Q1 QPD payment (25% of est. tax)	Past due
25 Jun 2026	Q2 QPD payment	Upcoming
Monthly	VAT7 return (by 25th each month)	Recurring
Monthly	P2 PAYE return (employees)	Recurring
31 Dec 2026	PRAZ licence renewal	Upcoming

Accountant's Corner — Bookkeeping

IFRS-compliant financial records · Clean Planet Resources (Pvt) Ltd

Financial year ended 31 December 2025 · Prepared in accordance with International Financial Reporting Standards (IFRS) · Currency: USD

IFRS Compliant TIN: 2000994920 VAT: 220011789 FY2025

General Ledger

FY2025

Double-entry ledger accounts · All amounts in USD · Debit (Dr) / Credit (Cr)

Items that may be reclassified to profit or loss	$0
Items that will not be reclassified to profit or loss	$0
Total OCI for the year	$0